摘要:
Provided is an optical element having at least (a) a support polymeric film layer of film material having opposing first and second sides, (b) a second polymeric film layer having opposing first and second sides, the second layer including a film material exhibiting a light influencing property, and (c) optionally, an adhesive layer interposed between and connected to at least a portion of the first side of support layer (a) and the second side of second layer (b). The film material of support layer (a) and the film material of second layer (b) are the same or different.
摘要:
Sulfonated polymers are made by the direct polymerization of a sulfonated monomer to form the sulfonated polymers. The types of sulfonated polymers may include polysulfones or polyimides. The sulfonated polymers can be formed into membranes that may be used in proton exchange membrane fuel cells or as ion exchange membranes. The membranes formed from the sulfonated polymers exhibit improved properties over that of Nafion®. A heteropoly acid may be added to the sulfonated polymer to form a nanocomposite membrane in which the heteropoly acid is highly dispersed. The addition of a heteropoly acid to the sulfonated polymer increases the thermal stability of the membrane, enhances the conductivity above 100° C., and reduces the water uptake of the membrane.
摘要:
Methods of preparing a porous low-k dielectric material on a substrate are provided. The methods involve the use of ultraviolet radiation to react with and remove porogen from a porogen containing precursor film, leaving a porous low-k dielectric matrix. Methods using oxidative conditions and non-oxidative conditions are described. The methods described may be used to remove porogen from porogen-containing precursor films. The porogen may be a hydrocarbon such as a terpene (e.g., alpha-terpinene) or a norbornene (e.g., ENB). The resulting porous low-k dielectric matrix can then be annealed to remove water and remaining silanols capped to protect it from degradation by ambient conditions, which methods will also be described.
摘要:
In some embodiments, a clock generator is provided that provides a generator clock. The clock generator comprises a first clock source to provide a first clock and a second clock source to provide a second clock whose frequency at least indirectly tracks a supply to a clock distribution network. The clock generator selectably provides as the generator clock the first clock when the second clock leads the first clock and the second clock when it lags behind the first clock. Other embodiments are claimed and disclosed herein.
摘要:
The amplitude and phase errors of the modulation and demodulation in a transceiver are corrected by a self-calibration procedure in which a test signal is applied to the baseband input of the transmitter, and the output of the modulator is looped back to the input of the demodulator. The amplitude and phase errors of the resulting signal at the baseband output of the receiver are detected, and the contributions of the transmitter and receiver to the errors are separated and resolved into amplitude and phase components. Adjustments are then made to the amplitude and phase balance in the transmit and receive signal paths to correct the errors.
摘要:
The present invention is directed to a proxy cache preloader. According to an embodiment of the present invention, a Hyper Text Transfer Protocol (HTTP) client intermediary having a proxy cache is used to provide multiple client computing devices with access to Internet data in the cache. When a device needs access to Internet data (i.e., a web page), a preloader/refresh mechanism is employed which uses a preloader algorithm. In one embodiment, the preloader algorithm checks to see if the current request is for an HTTP Uniform Resource Locator (URL). If not, the data is re-loaded into the proxy cache. If the current request is a request for HTTP, the preloader mechanism determines if optimization is enabled for the URL. If not, the data is re-loaded into the proxy cache. Otherwise, an information retrieval method (e.g., an HTTP GET) optimization algorithm is employed.
摘要:
Trimethoxyphenyl substituted indole ligands have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin polymerization. Such compounds as well as related derivatives are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as pro-drugs, may well prove to be tumor selective vascular targeting and destruction chemotherapeutic agents or to have anti-angiogenesis activity resulting in the selective prevention and/or destruction of tumor cell vasculature.
摘要:
Trimethoxyphenyl substituted indole ligands have been discovered which demonstrate impressive cytotoxicity as well as a remarkable ability to inhibit tubulin polymerization. Such compounds as well as related derivatives are excellent clinical candidates for the treatment of cancer in humans. In addition, certain of these ligands, as prodrugs, may well prove to be tumor selective vascular targeting and destruction chemotherapeutic agents or to have anti-angiogenesis activity resulting in the selective prevention and/or destruction of tumor cell vasculature.
摘要:
Disclosed are cyclic peptide analogs that are MC-4 and/or MC-3 receptor ligands, the analogs having a structure according to Formula (I): wherein B, X, E, Z, D, G, M′, W, R, R1, R1′, R11, m, n, p and q are as described in the specification. The peptide analogs are useful in treating diseases that are mediated by the MC-4 and/or the MC-3 receptor. As such, the invention is directed to methods of treating body weight disorders, such as obesity, anorexia, and cachexia. The invention also relates to the treatment of CNS depression, behavior-related disorders, memory-related disorders, cardiovascular function, inflammation, sepsis, septic shock, cardiogenic shock, hypovolemic shock, sexual dysfunction, erectile dysfunction, muscle atrophy, diseases associated with nerve growth and repair, and intrauterine fetal growth. Also disclosed are pharmaceutical compositions comprising the peptide analogs of Formula (I).